According to Celldex Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.3625. At the end of 2022 the company had a P/E ratio of -18.6.
Year | P/E ratio | Change |
---|---|---|
2022 | -18.6 | -20.85% |
2021 | -23.6 | 187.79% |
2020 | -8.19 | 1232.67% |
2019 | -0.6143 | 222.52% |
2018 | -0.1905 | -95.14% |
2017 | -3.92 | 39.62% |
2016 | -2.81 | -76.53% |
2015 | -12.0 | -13.43% |
2014 | -13.8 | -41.75% |
2013 | -23.7 | 260.8% |
2012 | -6.58 | 185.91% |
2011 | -2.30 | -95.53% |
2010 | -51.5 | 1993.62% |
2009 | -2.46 | 17.09% |
2008 | -2.10 | 660.49% |
2007 | -0.2762 | -32.18% |
2006 | -0.4073 | -94.8% |
2005 | -7.83 | -29.85% |
2004 | -11.2 | -18.49% |
2003 | -13.7 | 190.97% |
2002 | -4.71 | -54.21% |
2001 | -10.3 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.